Elsevier

Analytical Biochemistry

Volume 151, Issue 1, 15 November 1985, Pages 169-177
Analytical Biochemistry

A method for purifying the platelet membrane glycoprotein IIb-IIIa complex

https://doi.org/10.1016/0003-2697(85)90067-3Get rights and content

Abstract

A method has been developed for the rapid isolation of platelet membrane glycoproteins (GP) IIb and IIIa. This method produces an excellent yield and does not require the prior isolation of platelet membranes. Outdated platelets were washed and solubilized in Triton X-100. Concanavalin A affinity chromatography was used to purify a platelet glycoprotein fraction. The concanavalin A-retained glycoproteins were eluted and adsorbed with a heparin-Sepharose column to remove a major contaminant, thrombospondin. Sephacryl S-300 gel filtration was used as the final purification step to remove most fibrinogen and low-molecular-weight contaminants. Wheat germ agglutinin affinity chromatography was used to completely remove trace amounts of fibrinogen. The purified GP IIb and GP IIIa were analyzed by sucrose gradient sedimentation and found to consist of heterodimer complexes.

References (32)

  • L.V. Parise et al.

    J. Biol. Chem

    (1985)
  • L.K. Jennings et al.

    J. Biol. Chem

    (1982)
  • T.J. Kunicki et al.

    Blood

    (1981)
  • G.O. Gogstad et al.

    Biochim. Biophys. Acta

    (1982)
  • N.A. Carrell et al.

    J. Biol. Chem

    (1985)
  • L.A. Fitzgerald et al.

    J. Biol. Chem

    (1985)
  • L.L.K. Leung et al.

    J. Biol. Chem

    (1981)
  • D. Pidard et al.

    J. Biol. Chem

    (1983)
  • P.J. Newman et al.

    Anal. Biochem

    (1983)
  • K.H. Weisgraber et al.

    J. Lipid Res

    (1980)
  • P.J. McConahey et al.
  • J.E.B. Fox et al.

    J. Biol. Chem

    (1983)
  • D.R. Phillips et al.

    J. Biol. Chem

    (1977)
  • J. Lawler et al.

    J. Biol. Chem

    (1982)
  • K.J. Clemetson et al.

    Biochim. Biophys. Acta

    (1977)
  • S.L. Marchesi et al.

    Biochim. Biophys. Acta

    (1979)
  • Cited by (122)

    • Antibodies causing thrombocytopenia in patients treated with RGD-mimetic platelet inhibitors recognize ligand-specific conformers of α <inf>IIb</inf>/β<inf>3</inf> integrin

      2012, Blood
      Citation Excerpt :

      RGDW peptide was synthesized and purified by the Peptide Core Laboratory (BloodCenter of Wisconsin). Murine mAbs specific for αIIb/β3 were produced in BALB/c mice immunized with αIIb/β3 purified from human platelets.27 Details of the immunization protocol and selection for hybridomas secreting αIIb/β3-specific mAbs have been described previously.28

    • Heparin promotes platelet responsiveness by potentiating αIIbβ3-mediated outside-in signaling

      2011, Blood
      Citation Excerpt :

      Interestingly, and relevant to this discussion, heparin has been shown to bind a number of transmembrane glycoproteins, including the Ig-superfamily member G6b,42 as well as the cell-surface integrins αvβ343,44 and α5β1.44 Whether heparin similarly binds αIIbβ3 has been controversial, as Fitzgerald et al purified αIIbβ3 from heparin-binding contaminants by allowing it to flow unbound through heparin-Sepharose beads as part of an early chromatographic purification protocol for this integrin,45 whereas Sobel et al reported that not only could detergent solubilized αIIbβ3 specifically bind to and become eluted from this affinity matrix, tritiated heparin became photoaffinity cross-linked to cell surface αIIbβ3 in intact platelets.12 Our observation that either of 2 different anti-glycoprotein IIb-IIIa receptor antagonists, abciximab and eptifibatide, are able to prevent platelet spreading on immobilized heparin (Figure 4A) and downstream heparin-initiated signal transduction (Figure 4B; supplemental Figure 4), taken together with the observation that both murine (Figure 3) and human (Figure 4C) platelets lacking functional αIIbβ3 receptors fail to react with or become activated by immobilized UFH, LMWH (supplemental Figure 1), or fondaparinux (supplemental Figure 2), all under conditions in which the major αIIβ3 ligand, fibrinogen, is absent, provide compelling evidence that these clinically used compounds interact directly with αIIbβ3, and not another platelet receptor, to initiate outside-in signaling.

    View all citing articles on Scopus
    View full text